Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. epiorgabolism

EPIORGABOLISM SIGNED

Diabetic nephropathy modelling in hESC-derived 3D kidney organoids

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIORGABOLISM project word cloud

Explore the words cloud of the EPIORGABOLISM project. It provides you a very rough idea of what is the project "EPIORGABOLISM" about.

tissue    enhancers    status    functional    kptcs    physiological    structural    esrd    dn    acting    background    nephropathy    therapeutic    reprograming    expertise    model    fibrosis    date    organoids    cas9    patients    evidences    hypothesize    drugs    stage    diabetes    molecular    regulators    engineered    aberrant    preclinical    pressure    encoding    diabetic    serve    crispr    recapitulate    treatment    renal    epithelial    epigenome    hesc    blood    differentiation    stages    vitro    glycaemic    epigenetic    stop    cells    disease    promoted    vivo    dna    progression    reprogramming    ing    architecture    genes    alterations    regeneration    kidney    mimic    signature    cell    occurring    proximal    acid    enzymes    tubular    models    tool    embryonic    links    dr    lack    mainly    chemistry    pathology    fatty    drug    stem    good    gained    discovery    elucidate    validated    genetic    metabolic    montserrat    promoters    oxidation    impediments    somatic    human    methylation    therapies    therapy    metabolism   

Project "EPIORGABOLISM" data sheet

The following table provides information about the project.

Coordinator		 FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA 

Organization address
address: CARRER BALDIRI REIXAC PLANTA 2A 10-12
city: BARCELONA
postcode: 8028
website: http://www.ibecbarcelona.eu

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-04-18   to  2021-08-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

Diabetic Nephropathy is the leading cause of end-stage renal disease (ESRD). To date, treatment of DN is mainly based on drugs acting on glycaemic and blood pressure control, as there is no validated therapy able to stop the progression towards renal failure. One of the main impediments for developing new therapies for DN has been the lack of a good preclinical model which can recapitulate important functional, structural, and molecular features of advanced human diabetic kidney disease. Here, we aim to develop a DN modelling using human Embryonic Stem Cell (hESC) derived kidney organoids which can recapitulate the in vivo architecture, functionality, and genetic signature of DN. Due to the increasing evidences that links aberrant DNA methylation with kidney fibrosis and metabolic reprograming in DN, we hypothesize that early DN progression is promoted by the metabolic alterations occurring in diabetic patients, resulting in the epigenetic reprogramming of kidney proximal tubular epithelial cells (KPTCs). Based in my background in the fields of metabolism and diabetes, together with the expertise of Dr. Montserrat in the field of somatic reprograming, DN and tissue regeneration/differentiation, this proposal seeks to:1) Elucidate the methylation status of the promoters/enhancers of genes encoding enzymes and regulators of fibrosis and fatty acid oxidation in proximal tubular cells obtained from diabetic patients at different stages of DN progression 2) Establish two in vitro models using hESC-derived kidney organoids; an engineered DN in vitro model, using CRISPR Cas9 to mimic the epigenome signature of DN patients and a physiological DN in vitro model which mimic the diabetic physiological chemistry. The information gained from this DN modelling will offer improved insight into disease pathology and progression. Moreover, it may also serve as a tool for drug discovery to identify therapeutic targets for DN.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIORGABOLISM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIORGABOLISM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

NarrowbandSSL (2019)

Development of Narrow Band Blue and Red Emitting Macromolecules for Solution-Processed Solid State Lighting Devices

Read More  

DEF2DEV (2019)

Identification of the mode of action of plant defensins during root development and plant defense responses.

Read More